Keywords: MolMed, GlaxoSmithKline, Gene therapy, Rare diseases, ADA-SCID

MolMed in deal with GlaxoSmithKline to develop production process for a gene therapy

Article | 09 August 2011

Print This

Italian biotech company MolMed (Milan: MLM) has signed an agreement with UK drugs giant GlaxoSmithKline (LSE: GSK) under which it ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in